EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY 4.0

Dacomitinib as a First‐Line Therapy for Advanced EGFR ‐Mutated Non‐Small Cell Lung Cancer Without Brain Metastases: A Multicenter Retrospective Observational Study

Ping-Chih Hsu, How-Wen Ko, Li-Chung Chiu, Shih-Hao Huang, Chung-Shu Lee, Yu-Ching Lin, Scott Chih-Hsi Kuo, Jia-Shiuan Ju, Chin-Chou Wang, Cheng-Ta Yang

Cancer Medicine · 2026

DOI: 10.1002/cam4.71659 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer Medicine, 2026. Verfasst von Ping-Chih Hsu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Thoracic Medicine, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan City, Taiwan. Hauptthemen laut MEDLINE: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Quinazolinones, Protein Kinase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chang Gung Memorial Hospital, Linkou.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Real‐world evidence regarding the use of dacomitinib as a first‐line therapy for advanced non‐small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations remains limited. This multicenter, retrospective cohort study aimed to evaluate the clinical outcomes of dacomitinib as a first‐line treatment in patients with untreated advanced EGFR‐mutant NSCLC without brain metastases. Patients and Methods This retrospective analysis included 161 patients with stage IIIB/IV EGFR‐mutant NSCLC without brain metastasis at baseline who received first‐line dacomitinib between October 2020 and August 2023 at four Taiwanese cancer centers. The primary outcomes included the objective response rate (ORR), progression‐free survival (PFS), overall survival (OS), predictive risk factors for PFS, and adverse events (AEs).

Results

The ORR was 64.0%, and the disease control rate (DCR) reached 91.3%. The median PFS was 20.93 months (95% CI: 17.55–24.32), and the median OS was 41.27 months (95% CI: 31.71–50.82). Multivariate analysis revealed that an Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≥ 2, bone metastasis, and liver metastasis were independent predictors of shorter PFS. Among patients who experienced disease progression and underwent rebiopsy, the secondary T790M mutation rate was 50.6%. Most treatment‐related AEs were grade 1–2 and manageable.

Conclusions

Dacomitinib demonstrated favorable efficacy and tolerability as a first‐line therapy in advanced NSCLC patients with common EGFR mutations (exon 19 deletion or L858R). A baseline ECOG PS ≥ 2 and the presence of bone or liver metastases were significantly associated with worse PFS, suggesting a need for additional therapeutic strategies in these subgroups.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsCarcinoma, Non-Small-Cell LungQuinazolinonesProtein Kinase InhibitorsHumansFemaleRetrospective StudiesErbB ReceptorsMaleMutationMiddle AgedAgedAdultAged, 80 and overBrain NeoplasmsProgression-Free SurvivalTreatment Outcome

Stichwörter der Autor:innen

common EGFR mutationdacomitinibepidermal growth factor receptor mutationnon‐small cell lung cancer (NSCLC)tyrosine kinase inhibitor

Substanzen

dacomitinibErbB ReceptorsQuinazolinonesEGFR protein, humanProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Division of Thoracic Medicine, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Taoyuan City, Taiwan.
  • Department of Medicine, College of Medicine, Chang Gung University, Taoyuan City, Taiwan.
  • Department of Thoracic Medicine, New Taipei Municipal TuCheng Hospital, New Taipei City, Taiwan.
  • Division of Thoracic Oncology, Department of Respiratory and Critical Care Medicine, Chang Gung Memorial Hospital, Chiayi Branch, Chiayi County, Taiwan.
  • Department of Respiratory Care, Chang Gung University of Science and Technology, Chiayi Campus, Chiayi County, Taiwan.
  • Division of Pulmonary & Critical Care Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City, Taiwan.

Förderung

  • Chang Gung Memorial Hospital, Linkou

Zitieren

APA

Hsu, P. C., Ko, H. W., Chiu, L. C., Huang, S. H., Lee, C. S., Lin, Y. C., Kuo, S. C., Ju, J. S., Wang, C. C., & Yang, C. T. (2026). Dacomitinib as a First‐Line Therapy for Advanced EGFR ‐Mutated Non‐Small Cell Lung Cancer Without Brain Metastases: A Multicenter Retrospective Observational Study. Cancer Medicine. https://doi.org/10.1002/cam4.71659

Vancouver

Hsu PC, Ko HW, Chiu LC, Huang SH, Lee CS, Lin YC, et al. Dacomitinib as a First‐Line Therapy for Advanced EGFR ‐Mutated Non‐Small Cell Lung Cancer Without Brain Metastases: A Multicenter Retrospective Observational Study. Cancer Medicine. 2026. doi:10.1002/cam4.71659

BibTeX
@article{Hsu2026,
  author = {Hsu, Ping-Chih and Ko, How-Wen and Chiu, Li-Chung and Huang, Shih-Hao and Lee, Chung-Shu and Lin, Yu-Ching and Kuo, Scott Chih-Hsi and Ju, Jia-Shiuan and Wang, Chin-Chou and Yang, Cheng-Ta},
  title = {Dacomitinib as a First‐Line Therapy for Advanced EGFR ‐Mutated Non‐Small Cell Lung Cancer Without Brain Metastases: A Multicenter Retrospective Observational Study},
  journal = {Cancer Medicine},
  year = {2026},
  doi = {10.1002/cam4.71659}
}
Kostenlos starten →